Regarding - exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation

Sep 30, 2026

A commentary reviewing a network pharmacology and experimental validation study on Banxia Xiexin decoction (BXD) for polycystic ovary syndrome. The author supports the work for combining in silico target prediction with in vivo evidence, but argues that comparing the complete formula with isolated candidate ingredients may suffer from pharmacokinetic non-comparability, complicating interpretation of synergistic effects. It also notes pathway results linking BXD to PI3K-AKT/MAPK are correlational and calls for functional blockade assays using pathway inhibitors to establish causality. The author concludes that addressing pharmacokinetics and adding functional validation would strengthen mechanistic and translational impact.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Introduction

Methodological concerns: pharmacokinetic comparability

Mechanistic pathway evidence and need for causality

Summary and future directions

AnnAls of Medicine 2026, Vol. 58, no. 1, 2609417 [https://doi.org/10.1080/07853890.2025.2609417](https://doi.org/10.1080/07853890.2025.2609417) Pharmacology Regarding: “exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation” We read with interest the study by hai et al. on the mechanisms of Banxia Xiexin decoction (BXD) in treating polycystic ovary syndrome (PcoS) [1] . The authors provide a valuable contribution by applying network pharmacology in silico predictions and validating them with in vivo experiments, offering important insights into this traditional formula. To build upon this valuable work, we believe two key methodological aspects warrant further discussion to enhance the interpretation of these findings. First, the study design compares the effects of the complete BXD formula against three putative active ingredients. This approach, while informative, raises concerns regarding pharmacokinetic comparability. The in vivo exposure (aDmE) of these compounds when administered within the complex matrix of the entire decoction is unlikely to be equivalent to their exposure when administered in isolation. Therefore, interpreting the therapeutic differences between these groups becomes challenging, and the foundational, synergistic principles of holistic traditional formulas may be overlooked [2,3] . Second, the study insightfully identifies an association between BXD’s effects and the PI3K-aKT/maPK pathways. These findings are important, but they currently establish a correlation rather than a definitive causal link. To substantially strengthen this mechanistic claim, a crucial next step would be functional validation, such as a blockade assay. Demonstrating that BXD’s therapeutic effects are attenuated or abolished by specific pathway inhibitors would provide the necessary evidence to confirm that these pathways are dependent drivers of the observed efficacy [4,5] . In summary, hai et al. have provided an important foundation for understanding BXD. We suggest that future studies would be greatly enhanced by addressing the pharmacokinetic complexities of the holistic formula versus its components and by incorporating functional assays to confirm causal pathways. These steps would help solidify the interpretation of this work and guide the future pharmacological development of traditional medicines. Acknowledgments Junya Shen contributed to the conceptualization of the commentary, writing of the original draft, and review and editing of the manuscript. Disclosure statement No potential conflict of interest was reported by the author(s) . Funding The author(s) reported there is no funding associated with the work featured in this article. Data availability statement Data sharing is not applicable to this article as no data were created or analysed in this study. References [1] hai B, Zhang y, huang J, et al. Exploring the key ingredients and mechanisms of Banxia Xiexin decoction for the treatment of polycystic ovary syndrome based on network pharmacology and experimental validation. ann med. 2025;57(1):2503921 . doi:10 . 1080/07853890 .2025.2503921. 2 J. ShEN [2] Qiao X, Wang Q, Wang S, et al. a 42-markers pharmacokinetic study reveals interactions of berberine and glycyrrhizic acid in the anti-diabetic chinese medicine formula gegen-Qinlian decoction. Front Pharmacol. 2018;9:622 . doi:10.3389/fphar.2018.00622 . [3] li c, Jia WW, yang Jl, et al. multi-compound and drug-combination pharmacokinetic research on chinese herbal medicines. acta Pharmacol Sin. 2022;43(12):3080–3095 . doi:10 . 1038/s41401-022-00983-7 . [4] Wang F, yin y, Nie X, et al. Protocatechuic acid alleviates polycystic ovary syndrome symptoms in mice by PI3K signaling in granulosa cells to relieve roS pressure and apoptosis. gynecol Endocrinol. 2023;39(1):[2228917. do](2228917. do)[i:](i:1

FAQs

What is the main methodological concern raised about the original BXD study design?

The comparison between the complete BXD formula and three isolated putative active ingredients may have pharmacokinetic non-comparability, making therapeutic differences harder to interpret.

Which signaling pathways are associated with BXD’s effects according to the commentary?

The commentary highlights an association between BXD effects and the PI3K-AKT/MAPK pathways.

What evidence is recommended to confirm that the identified pathways are causally involved?

Functional validation, such as blockade assays with specific pathway inhibitors, to show that BXD’s effects are attenuated or abolished.

Sep 30, 2026

Uploaded by นรินทร์